Edwards Lifesciences Stock Hits Day Low of $81.34 Amid Price Pressure

Edwards Lifesciences Corp., a prominent player in the Pharmaceuticals & Biotechnology sector, experienced a notable decline of 3.31% on March 13, 2026. The stock reached an intraday low of USD 81.34, reflecting a challenging trading day. In terms of performance metrics, Edwards Lifesciences has shown mixed results over various time frames. Over the past week, the stock has gained 0.21%, contrasting with a 1.6% decline in the S&P 500. However, its one-month performance stands at a robust 7.83%, significantly outperforming the S&P 500's drop of 2.98%. Year-to-date, the stock has seen a decrease of 4.04%, slightly worse than the S&P 500's decline of 3.12%. Despite the recent downturn, Edwards Lifesciences maintains a strong market position with a market capitalization of USD 47.65 billion. The company boasts a high return on equity (ROE) of 22.80%, indicating effective management efficiency. However, it is important to note that the stock's performance over the past three years has lagged behind the S&P 500, with a growth of only 6.77%.